{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:51:52Z","timestamp":1783021912431,"version":"3.54.6"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The age of psoriasis onset is bimodally distributed with distinct peaks at &amp;lt; 40 (early onset) and \u2265 40\u2005years (late onset) of age. Although the age of psoriasis onset is associated with distinct disease profiles, few well-controlled studies have reported the efficacy of biologics in patients with early- vs. late-onset disease. The efficacy and safety of tildrakizumab, an interleukin-23 p19 inhibitor, for the treatment of moderate-to-severe plaque psoriasis were investigated in the reSURFACE 1 (NCT01722331) and reSURFACE 2 (NCT01729754) phase III trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To determine the efficacy and safety of tildrakizumab in patients with early- vs. late-onset psoriasis through 28 weeks of treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a post hoc subgroup analysis of patients from reSURFACE 1 and reSURFACE 2. Patients aged \u2265 50\u2005years were grouped by age of psoriasis onset (&amp;lt; 40\u2005years vs. \u2265 40\u2005years). Efficacy endpoints included absolute Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI), and the proportions of patients who achieved a \u2265 75%, \u2265 90% or 100% improvement from baseline in PASI (PASI 75, PASI 90 and PASI 100, respectively), a Physician Global Assessment score of 0 or 1 (PGA 0\/1) and DLQI of 0 or 1 (DLQI 0\/1), adjusted for potential confounders. Safety was assessed based on treatment-emergent adverse events (TEAEs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Higher percentages and adjusted responder rate estimates of patients with late- (n = 130) vs. early-onset (n = 111) psoriasis achieved an absolute PASI &amp;lt; 1 (36.2% vs. 27.9%; estimate was 32.2% vs. 25.0%), PASI 90 (50.8% vs. 39.6%; estimate was 49.4% vs. 40.2%) and PASI 100 (21.5% vs. 8.1%; estimate was 13.7% vs. 7.9%) at week 28 (all P &amp;lt; 0.05). Age of onset did not significantly affect change from baseline in absolute PASI or DLQI, or the achievement of PASI &amp;lt; 5, PASI &amp;lt; 3, PASI 75, DLQI 0\/1 or PGA 0\/1 (all P &amp;gt; 0.05). Efficacy findings were supported in a subset of patients matched by disease duration. TEAEs and serious TEAEs occurred in 65.8% vs. 66.2% and 3.6% vs. 6.9% of patients with early- vs. late-onset psoriasis, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Treatment with tildrakizumab was effective with no safety signals found in either of the patient subgroups. Patients with late-onset psoriasis were more likely to achieve complete or near-complete clearance than patients with early-onset psoriasis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljaf171","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T08:11:18Z","timestamp":1747123878000},"page":"442-450","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of tildrakizumab in patients with early- vs. late-onset psoriasis"],"prefix":"10.1093","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0064-8707","authenticated-orcid":false,"given":"April W","family":"Armstrong","sequence":"first","affiliation":[{"name":"Division of Dermatology, University of California , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2633-985X","authenticated-orcid":false,"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[{"name":"Blauvelt Consulting LLC , Annapolis, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6127-3182","authenticated-orcid":false,"given":"Akihiko","family":"Asahina","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Jikei University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranga","family":"Gogineni","sequence":"additional","affiliation":[{"name":"Sun Pharmaceutical Industries, Inc. , Princeton, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5371-4427","authenticated-orcid":false,"given":"Christopher E M","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Centre for Dermatology Research, The University of Manchester , Manchester ,","place":["UK"]},{"name":"Department of Dermatology, King\u2019s College Hospital, King\u2019s College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"2025081809371571200_ljaf171-B1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0190-9622(85)70188-0","article-title":"Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris","volume":"13","author":"Henseler","year":"1985","journal-title":"J Am Acad Dermatol"},{"key":"2025081809371571200_ljaf171-B2","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/1346-8138.14321","article-title":"Relationship between environmental factors, age of onset and familial history in Japanese patients with psoriasis","volume":"45","author":"Bayaraa","year":"2018","journal-title":"J Dermatol"},{"key":"2025081809371571200_ljaf171-B3","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1111\/jdv.15762","article-title":"Incidence and prevalence of psoriasis in Israel between 2011 and 2017","volume":"33","author":"Schonmann","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025081809371571200_ljaf171-B4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000247341","article-title":"Bimodality in age of onset of psoriasis, in both patients and their relatives","volume":"186","author":"Smith","year":"1993","journal-title":"Dermatology"},{"key":"2025081809371571200_ljaf171-B5","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1346-8138.1999.tb02066.x","article-title":"Characterization of early and late onset psoriasis in the Korean population","volume":"26","author":"Youn","year":"1999","journal-title":"J Dermatol"},{"key":"2025081809371571200_ljaf171-B6","doi-asserted-by":"crossref","first-page":"400","DOI":"10.2340\/00015555-3130","article-title":"Psoriasis incidence and lifetime prevalence: suggestion for a higher mortality rate in older age-classes among psoriatic patients compared to the general population in Italy","volume":"99","author":"Pezzolo","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"2025081809371571200_ljaf171-B7","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"2025081809371571200_ljaf171-B8","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"2025081809371571200_ljaf171-B9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5021\/ad.2021.33.1.61","article-title":"A large-scale, stratified genetic analysis of the major histocompatibility complex region in early- and late-onset psoriasis in China","volume":"33","author":"Zhou","year":"2021","journal-title":"Ann Dermatol"},{"key":"2025081809371571200_ljaf171-B10","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/bjd.14886","article-title":"Early- and late-onset psoriasis: a cross-sectional clinical and immunocytochemical investigation","volume":"175","author":"Theodorakopoulou","year":"2016","journal-title":"Br J Dermatol"},{"key":"2025081809371571200_ljaf171-B11","doi-asserted-by":"crossref","first-page":"101879","DOI":"10.1155\/2015\/101879","article-title":"Polymorphisms associated with age at onset in patients with moderate-to-severe plaque psoriasis","volume":"2015","author":"Prieto-Perez","year":"2015","journal-title":"J Immunol Res"},{"key":"2025081809371571200_ljaf171-B12","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/bjd.16083","article-title":"HLA-Cw6 and psoriasis","volume":"178","author":"Chen","year":"2018","journal-title":"Br J Dermatol"},{"key":"2025081809371571200_ljaf171-B13","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1046\/j.1523-1747.1999.00724.x","article-title":"HLA-Cw6 and the genetic predisposition to psoriasis: a meta-analysis of published serologic studies","volume":"113","author":"Mallon","year":"1999","journal-title":"J Invest Dermatol"},{"key":"2025081809371571200_ljaf171-B14","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/sj.jid.5700118","article-title":"Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients \u2013 an analysis of 1019 HLA-C- and HLA-B-typed patients","volume":"126","author":"Gudjonsson","year":"2006","journal-title":"J Invest Dermatol"},{"key":"2025081809371571200_ljaf171-B15","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1046\/j.1523-1747.2000.00863.x","article-title":"The association of psoriasis with human leukocyte antigens in Korean population and the influence of age of onset and sex","volume":"114","author":"Kim","year":"2000","journal-title":"J Invest Dermatol"},{"key":"2025081809371571200_ljaf171-B16","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/bjd\/ljad481","article-title":"The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)","volume":"190","author":"Alabas","year":"2024","journal-title":"Br J Dermatol"},{"key":"2025081809371571200_ljaf171-B17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2340\/00015555-0253","article-title":"Comparison of clinical features of HLA-Cw*0602-positive and -negative psoriasis patients in a Han Chinese population","volume":"87","author":"Fan","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"2025081809371571200_ljaf171-B18","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jaad.2022.07.050","article-title":"Type 1 and type 2 psoriasis revisited: no association between age at onset and disease course","volume":"87","author":"Svedbom","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2025081809371571200_ljaf171-B19","doi-asserted-by":"crossref","first-page":"e367","DOI":"10.1111\/ijd.12396","article-title":"The age of onset of psoriasis and the relationship to clinical presentation of psoriasis: study of 404 patients from northern Poland","volume":"53","author":"Szczerkowska-Dobosz","year":"2014","journal-title":"Int J Dermatol"},{"key":"2025081809371571200_ljaf171-B20","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/jdv.12850","article-title":"Psoriasis in the elderly: epidemiological and clinical aspects, and evaluation of patients with very late onset psoriasis","volume":"30","author":"Phan","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025081809371571200_ljaf171-B21","volume-title":"Full Prescribing Information","year":"2023"},{"key":"2025081809371571200_ljaf171-B22","volume-title":"Full Prescribing Information","year":"2024"},{"key":"2025081809371571200_ljaf171-B23","volume-title":"Full Prescribing Information","year":"2022"},{"key":"2025081809371571200_ljaf171-B24","volume-title":"Full Prescribing Information","year":"2024"},{"key":"2025081809371571200_ljaf171-B25","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"2025081809371571200_ljaf171-B26","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1111\/jdv.18167","article-title":"Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2","volume":"36","author":"Fernandez","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025081809371571200_ljaf171-B27","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jaad.2019.09.042","article-title":"Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)","volume":"82","author":"Lebwohl","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025081809371571200_ljaf171-B28","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jaad.2020.09.047","article-title":"Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)","volume":"84","author":"Lebwohl","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2025081809371571200_ljaf171-B29","doi-asserted-by":"crossref","first-page":"e15741","DOI":"10.1111\/dth.15741","article-title":"Interleukin-23 inhibitors demonstrate high effectiveness in the treatment of a real-world cohort of 82 psoriatic patients regardless of the HLA-Cw6 status","volume":"35","author":"Rubio-Muniz","year":"2022","journal-title":"Dermatol Ther"},{"key":"2025081809371571200_ljaf171-B30","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/bjd.21768","article-title":"Incidence and prevalence of psoriasis in multiethnic Johor Bahru, Malaysia: a population-based cohort study using electronic health data routinely captured in the Teleprimary Care (TPC\u00ae) clinical information system from 2010 to 2020: classification: epidemiology","volume":"187","author":"Choon","year":"2022","journal-title":"Br J Dermatol"},{"key":"2025081809371571200_ljaf171-B31","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u00a0\u2013 a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"2025081809371571200_ljaf171-B32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/bjd.12631","article-title":"Bimodal immune activation in psoriasis","volume":"170","author":"Christophers","year":"2014","journal-title":"Br J Dermatol"},{"key":"2025081809371571200_ljaf171-B33","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1002\/ski2.263","article-title":"No impact of disease duration on response to tildrakizumab treatment among patients with moderate-to-severe plaque psoriasis: post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies","volume":"3","author":"Griss","year":"2023","journal-title":"Skin Health Dis"},{"key":"2025081809371571200_ljaf171-B34","doi-asserted-by":"crossref","first-page":"e34594","DOI":"10.1371\/journal.pone.0034594","article-title":"Heterogeneity of inflammatory and cytokine networks in chronic plaque psoriasis","volume":"7","author":"Swindell","year":"2012","journal-title":"PLOS ONE"},{"key":"2025081809371571200_ljaf171-B35","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1038\/ncomms7916","article-title":"Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility","volume":"6","author":"Yin","year":"2015","journal-title":"Nat Commun"},{"key":"2025081809371571200_ljaf171-B36","doi-asserted-by":"crossref","first-page":"842651","DOI":"10.3389\/fimmu.2022.842651","article-title":"Defining patient-level molecular heterogeneity in psoriasis vulgaris based on single-cell transcriptomics","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"2025081809371571200_ljaf171-B37","author":"American Academy of Dermatology"},{"key":"2025081809371571200_ljaf171-B38","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025081809371571200_ljaf171-B39","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/bjd.20140","article-title":"Defining trajectories of response in patients with psoriasis treated with biologic therapies","volume":"185","author":"Geifman","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025081809371571200_ljaf171-B40","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/09546634.2019.1626973","article-title":"Characterization of responder groups to secukinumab treatment in moderate to\u00a0severe plaque psoriasis","volume":"31","author":"Pinter","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"2025081809371571200_ljaf171-B41","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/jdv.15077","article-title":"Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study","volume":"32","author":"Talamonti","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025081809371571200_ljaf171-B42","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40257-020-00585-1","article-title":"HLA-Cw1 and psoriasis","volume":"22","author":"Huang","year":"2021","journal-title":"Am J Clin Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf171\/63173864\/ljaf171.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/3\/442\/63173864\/ljaf171.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/3\/442\/63173864\/ljaf171.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T13:37:28Z","timestamp":1755524248000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/193\/3\/442\/8130694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,5,14]]},"published-print":{"date-parts":[[2025,8,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf171","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,5,14]]}}}